Drug hope in MRSA fight

BRITISH scientists are working on a drug that could herald a breakthrough in efforts to cure MRSA.

Researchers are carrying out trials of a bactericidal compound, which they claim kills bacteria, with a view to developing a product for use in hospitals within three years.

Most antibiotics used to treat hospital bugs such as MRSA are bacteriostatic, meaning they prevent the growth of bacteria.

Brighton-based pharmaceutical company Destiny Pharma believes its compound — codenamed XF-73 — could hold the key to stamping out the potentially-fatal bug.

A study showed, even after 55 repeat exposures, MRSA bacteria did not develop resistance to the drug — which is applied as a gel into patients’ noses — as it does to antibiotics.

The research was led by Destiny Pharma’s chief executive Dr Bill Love.

“If it goes through clinical trials successfully, it really is a completely fundamental breakthrough,” he said.

He said he hoped NHS strategic health authorities would be willing to pay for XF-73 if it was approved by the National Institute for Clinical Excellence.

The company said: “Destiny Pharma has completed its Phase I clinical trials and this result is the latest of many which have shown XF-73’s high potential.”

The firm presented its findings to the EU Congress on Clinical Microbiology and Infectious Diseases in Barcelona last month.


These are the nail hues to choose this season, says Katie Wright.Perfectly polished: 5 autumn/winter nail trends you’ll actually want to wear

This early 19th-century table is one of a number of Irish lots at Sotheby’s Style, Furniture and Ceramics sale in New York on Thursday (October 24).Irish lots poised to add bite to Big Apple sale

Something for all at Hegarty’s auction in Bandon, says Des O’SullivanSomething for all at Hegarty’s auction in Bandon

Des O’Sullivan gives a preview of the Irish selection on offer at two sales in DublinPreview of the Irish selection on offer at two sales in Dublin

More From The Irish Examiner